PARIS (Reuters) - Use of Sanofi’s dengue vaccine, the world’s first approved shot against the mosquito-borne virus, is to be strictly limited due to evidence it can worsen the disease in people who have not previously been exposed to the infection. The French drugmaker said in a statement on Wednesday that as a result it would book a charge in its fourth-quarter results of around 100 million euros ($118.57 million).
